Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDUCATE: Immunogenicity of Adjuvanted Influenza Vaccine Among Healthcare Personnel
NCT06054269Phase 3Completed
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Nov 2022
- Primary completion
- Jul 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Fluzone Trivalent in influenza (2 arms), sponsored by Centers for Disease Control and Prevention. Primary endpoints: Hemagglutination Inhibition Geometric Mean Titers at 6 months, Seroconversion Rate at 6 months and 1 more. Started Nov 2022; status: completed.
02
Drugs
Fluzone Trivalent
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06054269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06054269.